This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Amazon plans to launch its first prototype satellites for Project Kuiper, an internet-from-space venture, in 2022. It's the first major step in the e-commerce giant's plan to rival SpaceX by building a network of satellites in space, providing internet to rural, underserved communities around the world. Loren Grush, senior science reporter for the Verge, discusses the project and how it could transform internet access moving forward.
The FDA is assessing whether the Moderna vaccine can cause heart problems in adolescents. Professor Peter Pitts, founder of the Center for Medicine in the Public Interest and former FDA Associate Commissioner, discusses what the FDA is looking into and what it means for the millions of kids yet to be vaccinated.
Pfizer posted an earnings beat in its third quarter, with revenue soaring over 134% thanks to solid Covid-19 vaccine sales. Pfizer also raised its outlook for the full-year, expecting revenue to surpass $80 billion. Peter Andersen, CEO & founder of Andersen Capital Management, joined Cheddar Movers to discuss.
Cheddar gets a look at Curiosity Stream's 'Ancient Oceans'; Deep-sea biologist Heather Bracken-Grissom sheds light on some of the monsters that we can and cannot explain lurking in the darkness of the ocean's depths; Tim Janssen, CEO of Sofar Ocean, discusses Sofar Ocean's latest round of Series B funding, and how Sofar Ocean is helping connect all five oceans to help everything from climate change to the global shipping industry.
Tim Janssen, CEO of Sofar Ocean, joins 'Cheddar Reveals' to discuss Sofar Ocean's latest round of Series B funding, and how Sofar Ocean is helping connect all five oceans to help everything from climate change to the global shipping industry.
Deep-sea biologist Heather Bracken-Grissom joins 'Cheddar Reveals' to shed light on some of the monsters that we can and cannot explain lurking in the darkness of the ocean's depths.
Leaders around the world have come together to discuss plans to bring action towards the Paris Agreement along with solutions on how to solve the evolving climate change crisis at the COP26 Summit. President and CEO of Center for International Environmental Law Carroll Muffett, joined Cheddar to discuss more.
Rachel Cleetus, the policy director and lead economist of the climate and energy program for the Union of Concerned Scientists, joined Cheddar to break down some of the key goals from the COP26 summit and why leaders must focus on the science of climate change instead of getting bogged down by petty politics and the fossil fuel industry. "The main thing they have to do, make sure we're cutting our emissions sharply within this decade because the science shows that we have to cut global emissions in half by 2030 if we're going to meet our goals of averting some of the most catastrophic impacts of climate change," she said.
Coastal cities around the world are grappling with sea level rise. And building a seawall? Not so fast. While a sea wall can be effective in certain scenarios, it can make the effects of sea level rise worse. That’s why municipalities are looking into creative alternatives.
